CHMP Recommends Approval of Lilly`s Baricitinib for the Treatment of Adults with Moderate to Severe Atopic Dermatitis
(WorldNews Germany)

CHMP Recommends Approval of Lilly`s Baricitinib for the Treatment of Adults with Moderate to Severe Atopic Dermatitis September 18, 2020 Positive Opinion is the First Regulatory Action for Baricitinib as an Atopic Dermatitis Medicine INDIANAPOLIS, Sept. 18, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Incyte (NASDAQ:INCY) announced today that the European Medicines Agency`s(EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for baricitinib for the treatment of adult patients with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy. This opinion marks the first step toward European regulatory approval for...